Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study

被引：5

作者：

Okauchi, Shinichiro ^{[1
]}

Numata, Takeshi ^{[2
,3
]}

Nawa, Takeshi ^{[4
,5
]}

Ichimura, Hideo ^{[4
,5
]}

Saito, Takefumi ^{[6
]}

Hayashihara, Kenji ^{[6
]}

Yamada, Hideyasu ^{[7
]}

Satoh, Hiroaki ^{[1
]}

Endo, Takeshi ^{[2
,3
]}

Inage, Yoshihisa ^{[2
,3
]}

Kaburagi, Takayuki ^{[8
]}

Kiyoshima, Moriyuki ^{[8
]}

Yamada, Yutaka ^{[8
]}

Tamura, Tomohiro ^{[8
]}

Saito, Kazuhito ^{[9
,10
]}

Inagaki, Masaharu ^{[9
,10
]}

Hizawa, Nobuyuki ^{[11
]}

Sato, Yukio ^{[11
]}

Shiozawa, Toshihiro ^{[11
]}

Sekine, Ikuo ^{[11
]}

Ishikawa, Hiroichi ^{[12
,13
]}

Kurihima, Koichi ^{[12
,13
]}

Sakai, Mitsuaki ^{[12
,13
]}

Kamiyama, Koichi ^{[14
]}

Kimura, Masaki ^{[14
]}

Kikuchi, Norihiro ^{[15
]}

Nakamura, Hiroyuki ^{[16
,17
]}

Furukawa, Kinya ^{[16
,17
]}

Kodama, Takahide ^{[18
]}

Miyazaki, Kunihiko ^{[18
]}

Yamashita, Takaaki ^{[19
]}

Hayashi, Shigen ^{[20
]}

Funayama, Yasunori ^{[21
]}

Nomura, Akihiro ^{[20
]}

机构：

[1] Univ Tsukuba, Mito Kyodo Gen Hosp, Mito Med Ctr, Div Resp Med, Mito, Ibaraki, Japan

[2] Mito Med Ctr, Div Resp Med, Mito, Ibaraki, Japan

[3] Mito Med Ctr, Div Thorac Surg, Mito, Ibaraki, Japan

[4] Hitachi Gen Hosp, Div Resp Med, Hitachi, Ibaraki, Japan

[5] Hitachi Gen Hosp, Div Thorac Surg, Hitachi, Ibaraki, Japan

[6] Ibarakihigashi Hosp, Div Resp Med, Tokai, Ibaraki, Japan

[7] Univ Tsukuba, Div Resp Med, Hitachinaka Med Ctr, Mito, Ibaraki, Japan

[8] Ibaraki Cent Hosp, Resp Ctr, Kasama, Ibaraki, Japan

[9] Tsuchiura Kyodo Gen Hosp, Div Resp Med, Tsuchiura, Ibaraki, Japan

[10] Tsuchiura Kyodo Gen Hosp, Div Thorac Surg, Tsuchiura, Ibaraki, Japan

[11] Univ Tsukuba, Fac Clin Med, Tsukuba, Ibaraki, Japan

[12] Tsukuba Med Ctr Hosp, Div Resp Med, Tsukuba, Ibaraki, Japan

[13] Tsukuba Med Ctr Hosp, Div Thorac Surg, Tsukuba, Ibaraki, Japan

[14] Tsukuba Kinen Hosp, Div Thorac Surg, Tsukuba, Ibaraki, Japan

[15] Kasumigaura Med Ctr, Div Resp Med, Tsuchiura, Ibaraki, Japan

[16] Tokyo Med Univ, Ibaraki Med Ctr, Div Resp Med, Ami, Ibaraki, Japan

[17] Tokyo Med Univ, Ibaraki Med Ctr, Div Thorac Surg, Ami, Ibaraki, Japan

[18] Ryugasaki Saiseikai Hosp, Div Resp Med, Ryugasaki, Japan

[19] JA Toride Med Ctr, Div Resp Med, Toride, Japan

[20] Seinan Med Ctr, Div Resp Med, Sakai, Osaka, Japan

[21] Tsukuba Gakuen Gen Hosp, Div Resp Med, Tsukuba, Ibaraki, Japan

来源：

ANTICANCER RESEARCH | 2020年 / 40卷 / 02期

关键词：

Clinical practice; alectinib; non-small cell lung cancer; anaplastic lymphoma kinase fusion gene mutation; chemotherapy; KINASE INHIBITION; TYROSINE KINASE; CRIZOTINIB; THERAPY; CHEMOTHERAPY; ALECTINIB; SURVIVAL;

D O I：

10.21873/anticanres.14029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: To describe real clinical outcomes when using systemic therapy to treat non-small cell lung cancer (NSCLC) patients who have anaplastic lymphoma kinase (ALK) fusion gene mutation. Patients and Methods: We performed a retrospective chart review from April 2008 to March 2019 sourced from 16 medical institutes that cover a population of three million people. Results: There were 129 ALK rearranged NSCLC patients. Among them, 103 patients including 40 recurrent disease cases received ALK-tyrosine kinase inhibitors (TKI) and chemotherapy. Our treatment results were comparable to previously reported clinical trials and clinical practice studies. First-line alectinib, treatment sequence of ALK-TKI followed by another ALK-TKI, and pemetrexed-containing chemotherapy contributed to the outcome of treatment. Conclusion: By arrangement of treatment such as treatment sequence of ALK-TKI and chemotherapy regimen, it might be possible to obtain a treatment outcome almost equivalent to those of clinical trials even in real clinical practice.

引用

下载

页码：957 / 964

页数：8

共 50 条

[41] Treatment of advanced ALK-rearranged NSCLC following second-generation ALK-TKI failure
Fukuda, Akito
Yoshida, Tatsuya
EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (11) : 1157 - 1167
[42] Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib
Muller, Ittai B.
De Langen, Adrianus J.
Honeywell, Richard J.
Giovannetti, Elisa
Peters, Godefridus J.
EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (02) : 147 - 157
[43] Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
Takeyasu, Yuki
Yoshida, Tatsuya
Masuda, Ken
Matsumoto, Yuji
Shinno, Yuki
Okuma, Yusuke
Goto, Yasushi
Horinouchi, Hidehito
Yamamoto, Noboru
Ohe, Yuichiro
JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (05):
[44] ALKternate: A Proof of Concept Study in ALK-Rearranged NSCLC Alternating Lorlatinib with Crizotinib After Disease Progression
Itchins, M.
Hayes, S.
Hudson, A.
Howell, V.
Tan, S. W. D.
Clarke, S.
Solomon, B.
Pavlakis, N.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S642 - S643
[45] ALKternate: A Proof of Concept Study in ALK-Rearranged NSCLC Alternating Lorlatinib With Crizotinib After Disease Progression
Itchins, M.
Liang, S.
Brown, C.
Solomon, B.
Pavlakis, N.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1101 - S1102
[46] First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK plus ) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)
De Castro, Gilberto, Jr.
Tan, Daniel Shao-Weng
Crino, Lucio
Wu, Yi Long
Paz-Ares, Luis
Wolf, Juergen
Geater, Sarayut
Orlov, Sergey
Cortinovis, Diego
Yu, Chong-Jen
Hochmair, Maximilian
Cortot, Alexis
Tsai, Chun-Ming
Moro-Sibilot, Denis
Campelo, Rosario Garcia
Branle, Fabrice
Sen, Paramita
Mcculloch, Tracey
Soria, Jean-Charles
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S7 - S7
[47] Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
Dagogo-Jack, Ibiayi
Kiedrowski, Lesli A.
Heist, Rebecca S.
Lin, Jessica J.
Meador, Catherine B.
Krueger, Elizabeth A.
Do, Andrew
Peterson, Jennifer
V. Sequist, Lecia
Gainor, Justin F.
Lennerz, Jochen K.
Digumarthy, Subba R.
JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (08):
[48] Alectinib in ALK-Rearranged NSCLC Patients Following Crizotinib. Final Results and Biological Outcomes - Phase II ATALK Study
Cortot, A.
Escande, F.
Gervais, R.
Greillier, L.
Corre, R.
Veillon, R.
Ionescu, M.
Felicio, H.
Pau, D.
Gregoire, V.
Girard, N.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S658 - S658
[49] Dissecting the landscape of CAF-mediated drug resistance mechanisms in ALK-rearranged NSCLC
Hu, Q.
Rix, L. L. Remsing
Li, X.
Welsh, E. A.
Fang, B.
Yun, S.
Kroeger, J.
Lawrence, H. R.
Marusyk, A.
Koomen, J. M.
Haura, E. B.
Rix, U.
EUROPEAN JOURNAL OF CANCER, 2020, 138 : S48 - S48
[50] Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC
Tran, Phu N.
Klempner, Samuel J.
FRONTIERS IN MEDICINE, 2016, 3 : 1 - 6

← 1 2 3 4 5 →